Latamoxef
From Wikipedia, the free encyclopedia
Latamoxef
|
|
Systematic (IUPAC) name | |
(6R,7R)-7-{[3-hydroxy-2-(4-hydroxyphenyl)-3- oxopropanoyl]amino}-7-methoxy-3-[(1-methyltetrazol- 5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid |
|
Identifiers | |
CAS number | |
ATC code | J01 |
PubChem | |
Chemical data | |
Formula | C20H20N6O9S |
Mol. mass | 520.474 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 35 to 50% |
Metabolism | Nil |
Half life | 2 hours |
Excretion | Mostly renal, unchanged; also biliary |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Intramuscular, intravenous |
Latamoxef (or moxalactam) is an oxacephem antibiotic usually grouped with the cephalosporins. In oxacephems such as latamoxef, the sulfur atom of the cephalosporin core is replaced with an oxygen atom.
Latamoxef has been associated with prolonged bleeding time, and several cases of coagulopathy, some fatal, were reported during the 1980s.[1][2] Latamoxef is no longer available in the United States.
[edit] References
- ^ Weitekamp MR, Aber RC (1983). "Prolonged bleeding times and bleeding diathesis associated with moxalactam administration". JAMA 249 (1): 69–71. PMID 6217353.
- ^ Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M (1986). "Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients". Arch Intern Med 146 (11): 2159–64. PMID 3778044.
|